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2Abstract
Previously, we reported that intracerebroventricularly
(i.c.v.) administered arginine-vasopressin evokes the 
secretion of noradrenaline and adrenaline from adrenal medulla 
through the brain phospholipase C- and diacylglycerol-mediated 
and cyclooxygenase-mediated mechanisms in rats. Diacylglycerol 
can be hydrolyzed by diacylglycerol lipase to 2-arachidonoyl-
sn-glycerol, which may be further degradated by 
monoacylglycerol lipase to free arachidonic acid, a 
representative substrate of cyclooxygenase. Recently, 2-
arachidonoyl-sn-glycerol has been recognized as a major 
endocannabinoid, which can modulate synaptic transmission in 
the brain. In the present experiment, therefore, we examined 
(1) a role of the brain 2-arachidonoyl-sn-glycerol as a 
precursor of arachidonic acid in the centrally administered 
vasopressin-induced elevation of plasma noradrenaline and 
adrenaline, and (2) a regulatory role of the brain 2-
arachidonoyl-sn-glycerol as an endocannabinoid on the 
vasopressin-induced response, using urethane-anesthetized 
rats. The vasopressin (0.2 nmol/animal, i.c.v.)-induced 
elevation of plasma catecholamines was reduced by RHC-80267 
(diacylglycerol lipase inhibitor) (1.3 and 2.6 ?mol/animal,
i.c.v.) and also reduced by MAFP (monoacylglycerol lipase 
inhibitor) (0.7 and 1.4 ?mol/animal, i.c.v.). MAFP (1.4 
3?mol/animal, i.c.v.) also attenuated the 2-arachidonoyl-sn-
glycerol (0.5 ?mol/animal, i.c.v.)-induced elevation of plasma 
catecholamines. AM 251 (cannabinoid CB1 receptor antagonist) 
(90 and 180 nmol/animal, i.c.v.) potentiated the vasopressin 
(0.2 nmol/animal, i.c.v.)-induced response, while AM 630 
(cannabinoid CB2 receptor antagonist) (198 and 793 
nmol/animal, i.c.v.) was largely ineffective. In addition, WIN 
55212-2 (cannabinoid CB receptor agonist) (188 and 470 
nmol/animal, i.c.v.) dose-dependently reduced the vasopressin-
induced response. These results suggest that the brain 2-
arachidonoyl-sn-glycerol generated from diacylglycerol plays a 
role as a precursor of arachidonic acid in the centrally 
administered vasopressin-induced activation of the 
adrenomedullary outflow, and also negatively regulates the 
peptide-induced central response through the brain cannabinoid 
CB1 receptors in rats.
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41.  Introduction
Vasopressin has been recognized as an important 
neuropeptide involved in water conservation (Acher, 1993) and 
pituitary adrenocorticotropic hormone secretion (Antoni, 1984; 
Rivier et al., 1984). The peptide is also recognized as a 
neurotransmitter or neuromodulator to modulate diverse brain 
functions such as memory and behavior (De Wied et al., 1991; 
Drago et al., 1997; Bielsky et al., 2005), fever (Wilkinson 
and Kasting, 1987) and central cardiovascular regulation 
(Milutinovic et al., 2006). Previously, we reported that the 
centrally administered vasopressin elevated plasma 
noradrenaline and adrenaline and this elevation was attenuated 
by centrally administered indomethacin, an inhibitor of 
cyclooxygenase, and also abolished by bilateral adrenalectomy 
(Okada et al., 2003). These results suggest that the brain 
vasopressin activates the central adrenomedullary outflow by 
the brain cyclooxygenase-mediated mechanisms in rats.
Recently, we reported that the vasopressin-induced 
elevation of plasma catecholamines is mediated by the brain 
phospholipase C- and diacylglycerol-mediated mechanisms in 
rats (Shimizu et al., 2004). Phospholipase C cleaves the 
phosphodiester bond of membrane phospholipids, resulting the 
formation of diacylglycerol (Rebecchi and Pentyala, 2000). 
Diacylglycerol can be hydrolyzed by diacylglycerol lipase, 
which is more selective for the sn-1 over the sn-2 position of 
diacylglycerol (Bisogno et al., 2003), to produce 2-
arachidonoyl-sn-glycerol (Konrad et al., 1994; Stella et al., 
1997; Bisogno et al., 2003; Gauthier et al., 2005; Tang et al. 
52006). 2-Arachidonoyl-sn-glycerol can be further metabolized 
by monoacylglycerol lipase to free arachidonic acid, a 
representative substrate of cyclooxygenase (Konrad et al., 
1994; Karlsson et al., 1997; Dinh et al., 2002; Tang et al. 
2006).
2-Arachidonoyl-sn-glycerol has been recognized as a major 
endocannabinoid for the brain cannabinoid CB receptors 
(Sugiura et al., 1995; Sugiura and Waku, 2000; De Petrocellis 
et al., 2004). Endocannabinoids such as 2-arachidonoyl-sn-
glycerol and anandamide have been shown to have regulatory 
effects on the sympathetic nervous system (Ishac et al., 1996; 
Seagard et al., 2004; Brozoski et al., 2005), in addition to a 
wide range of central effects including pain processing 
(Hohmann et al., 2005), neuroprotection (Melis et al., 2006; 
Kreitzer and Malenka, 2007), depression (Gobbi et al., 2005) 
and neuroendocrine secretion (Patel et al., 2004). 
In the present study, therefore, we pharmacologically 
examined (1) a role of the brain 2-arachidonoyl-sn-glycerol as 
a precursor of arachidonic acid in the centrally administered 
vasopressin-induced elevation of plasma catecholamines. 
Furthermore, we examined (2) a regulatory role of 2-
arachidonoyl-sn-glycerol as an endocannabinoid on the 
vasopressin-induced response in rats. 
62.  Materials and methods
2.1.  Experimental procedures
Male Wistar rats weighing about 350 g were maintained in 
an air-conditioned room at 22-24°C under a constant day-night 
rhythm for more than 2 weeks and given food (laboratory chow, 
CE-2; Clea Japan, Hamamatsu, Japan) and water ad libitum. 
Under urethane anesthesia (1.2 g/kg, i.p.), the femoral vein 
was cannulated for infusion of saline (1.2 ml/h), and the 
femoral artery was cannulated for collecting blood samples. 
After these procedures, the animal was placed in a stereotaxic 
apparatus, as shown in our previous papers (Yokotani et al., 
1995; Shimizu et al., 2004). The skull was drilled for 
intracerebroventricular administration of test substances 
using stainless-steel cannula (0.3 mm outer diameter). The
stereotaxic coordinates of the tip of cannula were as follows 
(in mm): AP -0.8, L 1.5, V 4.0 (AP, anterior from the bregma; 
L, lateral from the midline; V, below the surface of the 
brain), according to the rat brain atlas (Paxinos and Watson, 
1986). Three hours were allowed to elapse before the start of 
each experiment.
RHC-80267 [1,6-bis(cyclohexyloximinocarbonylamino)hexane], 
MAFP (methyl arachidonyl fluorophosphonate), AM 251 [N-
(piperidin-1-yl)-5-(4-iodophenyl)-1-(2,4-dichlorophenyl)-4-
methyl-1H-pyrazole-3-carboxamide], AM 630 [(6-iodo-2-methyl-1-
[2-(4-morpholinyl)ethyl]-1H-indol-3-yl)(4-
methoxyphenyl)methanone], WIN 55212-2 [(R)-(+)-[2,3-dihydro-5-
methyl-3-(4-morpholinylmethyl)pyrrolo[1,2,3-de]-1,4-
7benzoxazin-6-yl]-1-naphthalenylmethanone], and 2-arachidonoyl-
sn-glycerol dissolved in 2.5 ?l of 100% N,N-dimethylformamide
(DMF)/animal were slowly administered into the right lateral 
ventricle using a 10-?l Hamilton syringe. Vasopressin 
dissolved in sterile saline in a volume of 10 ?l/animal was 
intracerebroventricularly (i.c.v.) administered using a 25-?l
Hamilton syringe 30 min after application of RHC-80267, MAFP, 
AM 251 and AM 630 and 60 min after application of WIN 55212-2, 
due to their slightly elevating effects on the basal plasma 
levels of catecholamines. 2-Arachidonoyl-sn-glycerol was 
i.c.v. administered 30 min after application of MAFP. Only one 
dose of these reagents was applied to each animal.
All experiments were conducted in compliance with the 
guiding principles for the care and use of laboratory animals 
approved by the Kochi University.
2.2.  Measurement of plasma catecholamines
Blood samples (250 ?l) were collected through an arterial 
catheter and were preserved on ice during experiments. Plasma 
was prepared immediately after the final sampling. 
Catecholamines in the plasma were extracted by the method of 
Anton and Sayre (1962) with a slight modification and were 
assayed electrochemically with high performance liquid 
chromatography (HPLC) (Shimizu et al., 2004). Briefly, after 
centrifugation, the plasma (100 ?l) was transferred to a 
centrifuge tube containing 30 mg of activated alumina, 2 ml of 
double deionized water, 1 ml of 1.5 M Tris Buffer (pH 8.6) 
containing 0.1 M disodium EDTA and 1 ng of 3,4-
8dihydroxybenzylamine as an internal standard. The tube was 
shaken for 10 min and the alumina was washed three times with 
4 ml of ice-cold double deionized water. Then, catecholamines 
adsorbed onto the alumina were eluted with 300 ?l of 4% acetic 
acid containing 0.1 mM disodium EDTA. A pump (EP-300: Eicom, 
Kyoto, Japan), a sample injector (Model-231XL; Gilson, 
Villiers-le-Bel, France) and an electrochemical detector (ECD-
300: Eicom) equipped with a graphite electrode were used with 
HPLC. Analytical conditions were as follows: detector, +450 mV 
potential against a Ag/AgCl reference electrode; column, 
Eicompack CA-50DS, 2.1 x 150 mm (Eicom); mobile phase, 0.1 M 
NaH2PO4-Na2HPO4 buffer (pH 6.0) containing 50 mg/l disodium 
EDTA, 0.75 g/l sodium 1-octanesulfonate and 15% methanol at a 
flow of 0.18 ml/min; injection volume, 40 ?l. The amount of 
catecholamines in each sample was calculated using the peak 
height ratio relative to that of 3,4-dihydroxybenzylamine. By 
this assay, coefficients of variation for intra- and inter-
assay were 3.0% and 3.7% respectively, and 0.5 pg of 
noradrenaline and adrenaline was accurately determined.
2.3.  Treatment of data and statistics 
All values are expressed as the means±S.E.M. The data were 
analyzed by repeated-measure analysis of variance (ANOVA), 
followed by post-hoc analysis with the Bonferroni method (Figs. 
1, 3 and 4). When only two means were compared, an unpaired 
Student’s t-test was used (Fig. 2). P values less than 0.05 
were taken to indicate statistical significance.
92.4.  Compounds 
The following drugs were used: synthetic arginine-
vasopressin (vasopressin) (Peptide Institute, Osaka, Japan); 
RHC-80267 and 2-arachidonoyl-sn-glycerol (Biomol Research 
Lab., Plymouth Meeting, PA, USA); MAFP (Cayman Chemical, Ann 
Arbor, MI, USA); AM 251 and WIN 55212-2 mesylate (Tocris 
Cookson Inc., Ellisville, Missouri, USA); AM 630 (Alexis 
Biochemicals, San Diego, CA, USA). All other reagents were the 
highest grade available (Nacalai Tesque, Kyoto, Japan).
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3.  Results
3.1.  Effects of RHC-80267 (an inhibitor of diacylglycerol 
lipase) and MAFP (an inhibitor of monoacylglycerol lipase) on 
the centrally administered vasopressin-induced elevation of 
plasma catecholamines
Treatments with vehicle-1 (2.5 ?l DMF/animal, i.c.v.) and 
vehicle-2 (10 ?l saline/animal, i.c.v.) had no effect on the 
basal plasma levels of noradrenaline and adrenaline (Fig. 1, A 
and B). Pretreatment with RHC-80267 [2.6 ?mol (1000 
?g)/animal, i.c.v.] or MAFP [1.4 ?mol (500 ?g)/animal, i.c.v.] 
also had no effect on the basal plasma levels of both 
catecholamines (Fig. 1, A and B).
Since we previously reported that vasopressin (0.1, 0.2 
and 0.5 nmol/animal, i.c.v.) dose-dependently elevated plasma 
levels of both catecholamines (Okada et al., 2002), we used a 
dose of 0.2 nmol/animal in the present experiment. I.c.v. 
administered vasopressin (0.2 nmol/animal) rapidly increased 
plasma levels of both catecholamines. These responses reached 
a maximum 5 min after administration of vasopressin and then 
declined toward their basal levels (Fig. 1, A and B). 
Intravenous administration of this dose of vasopressin had no 
effect on the basal plasma levels of catecholamines (data not 
shown).
The vasopressin (0.2 nmol/animal, i.c.v.)-induced 
elevation of both catecholamines was reduced by pretreatment 
with RHC-80267 in a dose-dependent manner [1.3 and 2.6 ?mol
(500 and 1000 ?g)/animal, i.c.v.] (Fig. 1A). The peptide-
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induced response was also attenuated by pretreatment with MAFP
[0.7 and 1.4 ?mol (250 and 500 ?g)/animal, i.c.v.] (Fig. 1B).
3.2.  Effect of MAFP (an inhibitor of monoacylglycerol lipase) 
on the centrally administered 2-arachidonoyl-sn-glycerol-
induced elevation of plasma catecholamines
Treatments with vehicle-1 (2.5 ?l DMF/animal, i.c.v.) and 
vehicle-2 (2.5 ?l DMF/animal, i.c.v.) had no effect on the 
basal plasma levels of noradrenaline and adrenaline (Fig. 2). 
Pretreatment with MAFP [1.4 ?mol (500 ?g)/animal, i.c.v.] also 
had no effect on the basal plasma levels of both 
catecholamines (Fig. 2).
I.c.v. administered 2-arachidonoyl-sn-glycerol [0.1, 0.5 
and 1.0 ?mol (38, 189 and 379 ?g)/animal] elevated plasma 
levels of both catecholamines and a maximal response was 
obtained at 0.5 ?mol/animal (data not shown). 2-Arachidonoyl-
sn-glycerol [0.5 ?mol/animal, i.c.v.] rapidly increased plasma 
levels of both catecholamines (adrenaline > noradrenaline) and 
these responses reached a maximum 5-10 min after 
administration of this reagent (Fig. 2). The reagent-induced 
response was effectively attenuated by pretreatment with MAFP 
(1.4 ?mol/animal, i.c.v.) (Fig. 2).
3.3.  Effects of AM 251 (a selective antagonist of 
cannabinoid CB1 receptors) and AM 630 (a selective antagonist 
of cannabinoid CB2 receptors) on the centrally administered 
vasopressin-induced elevation of plasma catecholamines 
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Pretreatment with AM 251 [180 nmol (100 ?g)/animal,
i.c.v.] or AM 630 [793 nmol (400 ?g)/animal, i.c.v.] had no 
effect on the basal plasma levels of noradrenaline and 
adrenaline (Fig. 3, A and B). 
Pretreatment with AM 251 [90 and 180 nmol (50 and 100 
?g)/animal, i.c.v.] dose-dependently potentiated the 
vasopressin (0.2 nmol/animal, i.c.v.)-induced elevation of 
plasma levels of both catecholamines (Fig. 3A). On the other 
hand, the vasopressin-induced response was largely unaffected
by pretreatment with AM 630 [198 and 793 nmol (100 and 400 
?g)/animal, i.c.v.] (Fig. 3B).  
3.4.  Effect of WIN 55212-2 (an agonist of cannabinoid CB 
receptors) on the centrally administered vasopressin-induced 
elevation of plasma catecholamines
Treatments with vehicle-1 (2.5 ?l DMF/animal, i.c.v.) and 
vehicle-2 (10 ?l saline/animal, i.c.v.) had no effect on the 
basal plasma levels of noradrenaline and adrenaline (Fig. 4). 
Pretreatment with WIN 55212-2 [470 nmol (250 ?g)/animal,
i.c.v.] also had no effect on the basal plasma levels of both 
catecholamines (Fig. 4).
The vasopressin (0.2 nmol/animal, i.c.v.)-induced 
elevation of both catecholamines was effectively reduced by 
pretreatment with WIN 55212-2 in a dose-dependent manner [188 
and 470 nmol (100 and 250 ?g)/animal, i.c.v.] (Fig. 4). 
Intravenous pretreatment of WIN 55212-2 [470 nmol (250 
?g)/animal] had no effect on the vasopressin-induced elevation 
of both catecholamines (data not shown). 
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4.  Discussion
2-Arachidonoyl-sn-glycerol is formed from arachidonic 
acid-enriched membrane phospholipids through phospholipase C-
and diacylglycerol lipase-mediated mechanisms (Stella et al., 
1997; Gauthier et al., 2005; Tang et al. 2006). Diacylglycerol 
lipase overexpression in mouse neuroblastoma increased basal 
2-arachidonoyl-sn-glycerol levels and this effect was 
accompanied by enhanced utilization of 1-stearoyl,2-
arachidonoyl-sn-glycerol (a precursor of 2-arachidonoyl-sn-
glycerol) (Jung et al., 2007). RHC-80267 has been shown to 
selectively inhibit diacylglycerol lipase activity in human 
adrenal glomerulosa cells and rat thyroid lobes (Levasseur et 
al., 1984; Natarajan et al., 1988), and also to inhibit 2-
arachidonoyl-sn-glycerol release in rat brain neurons and 
bovine coronary endothelial cells (Stella et al., 1997; 
Gauthier et al., 2005). In the first experiment, we examined 
the effect of RHC-80267 on the centrally administered 
vasopressin-induced elevation of plasma noradrenaline and 
adrenaline. The reagent effectively reduced the vasopressin-
induced response, suggesting that 2-arachidonoyl-sn-glycerol
generated from diacylglycerol by diacylglycerol lipase is 
involved in the vasopressin-induced activation of the central 
adrenomedullary outflow in rats.
2-Arachidonoyl-sn-glycerol can be oxygenated directly by 
cyclooxygenase to generate glycerol esters of prostaglandins 
and thromboxane A2 (Kozak et al., 2000, 2002), which may serve 
as a precursor of each prostanoid (Rouzer and Marnett, 2005). 
We previously reported that the sequential actions of the 
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brain cyclooxygenase and thromboxane A2 synthase are involved 
in the centrally administered vasopressin-induced elevation of 
plasma catecholamines in rats (Okada et al., 2003). However, 
thromboxane A2 synthase is far lesser efficient to catalyze 2-
arachidonoyl-sn-glycerol-derived glycerol ester of 
prostaglandin H2 than prostaglandin H2 to the corresponding 
thromboxanes by the sequential action of cyclooxygenase (Kozak 
et al., 2002). The evidence suggests that the brain 
thromboxane A2 is synthesized from the other pathway than 
glycerol ester of thromboxane A2 in the vasopressin-induced 
activation of adrenomedullary outflow in rats.
2-Arachidonoyl-sn-glycerol can be further hydrolyzed by 
monoacylglycerol lipase to generate free arachidonic acid 
(Konrad et al., 1994; Dinh et al., 2002; Tang et al. 2006), 
which is further metabolized to prostanoids (prostaglandins 
and thromboxane A2) by the sequential actions of 
cyclooxygenase and each prostanoid synthase. In the next 
experiment, we examined the effect of MAFP on the centrally 
administered vasopressin-induced elevation of plasma 
catecholamines. MAFP has been shown to be an inhibitor of 
phospholipase A2 or fatty acid amide hydrolase, but it is 
currently recognized as a very potent (IC50 value 2-3 nM) 
inhibitor of 2-arachidonoyl-sn-glycerol hydrolyzing enzymatic 
activity (Goparaju et al., 1999; Saario et al., 2004). MAFP
has been shown to accumulate endogenous 2-arachidonoyl-sn-
glycerol in rat brain sections by functional autoradiography
(Palomaki et al., 2007). In the present experiment, MAFP 
effectively attenuated the vasopressin-induced elevation of 
plasma catecholamines. Since the vasopressin-induced response 
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was not influenced by central pretreatment with mepacrine, an 
inhibitor of phospholipase A2 (Shimizu et al., 2004), the 
attenuating effect of MAFP on the vasopressin-induced response 
seems to be due to the inhibition of 2-arachidonoyl-sn-
glycerol hydrolyzing enzymatic activity, thereby reducing 
arachidonic acid production from 2-arachidonoyl-sn-glycerol.
We further examined the effect of MAFP on the centrally
administered 2-arachidonoyl-sn-glycerol-induced elevation of
plasma noradrenaline and adrenaline. The reagent also 
effectively attenuated the reagent-induced elevation of plasma 
catecholamines. Since centrally administered arachidonic acid 
itself elevated plasma catecholamines in rats (Yokotani et 
al., 2000), the attenuating effect of MAFP on the 2-
arachidonoyl-sn-glycerol-induced response is due to the 
inhibition of arachidonic acid production from 2-arachidonoyl-
sn-glycerol. These lines of evidence further support a 
possibility that the brain arachidonic acid generated from 2-
arachidonoyl-sn-glycerol by monoacylglycerol lipase is 
involved in the vasopressin-induced activation of 
adrenomedullary outflow in rats.
Recently, 2-arachidonoyl-sn-glycerol has been shown to act 
as an endocannabinoid on cannabinoid CB receptors in the 
central nervous system (Sugiura et al., 1995; Sugiura and 
Waku, 2000; De Petrocellis et al., 2004). So far two types of 
cannabinoid receptors (CB1 and CB2) have been identified 
(Matsuda et al., 1990; Munro et al., 1993). Cannabinoid CB1
receptors are expressed predominantly in the central nervous 
system, whereas cannabinoid CB2 receptors are present mainly 
in the immune system (Howlett et al., 2002). Recent studies 
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have also revealed the functional presence and expression of 
cannabinoid CB2 receptors in the central nervous system (Van 
Sickle et al., 2005; Onaivi, 2007). 
AM 251 and AM 630 have been shown to be a selective 
antagonist of cannabinoid CB1 and CB2 receptors, respectively 
(AM 251 is 306-fold selective over cannabinoid CB2 receptors 
and AM 630 is 165-fold over CB1 receptors) (Lan et al., 1999; 
Ross et al., 1999). AM 251 displays a Ki value of 7.49 nM at 
cannabinoid CB1 receptors (Lan et al., 1999) and AM 630 has a 
Ki value of 31.2 nM at cannabinoid CB2 receptors (Ross et al., 
1999). AM 251 reverses the cannabinoid CB receptor agonist WIN 
55212-2-induced synaptic suppression at hippocampal excitatory 
synapses on murine pyramidal neurons (Kawamura et al., 2006) 
and the intra-CA1 injection of WIN 55212-2-induced anxiogenic-
like effect in rats (Roohbakhsh et al., 2007). AM 630 prevents 
the intrathecally administered CP55940 (a synthetic 
cannabinoid)-induced analgesia in rat pain models (Romero-
Sandoval and Eisenach, 2007). 
In the next experiment, we examined a regulatory role of 
the brain 2-arachidonoyl-sn-glycerol generated from 
diacylglycerol as an endocannabinoid on the vasopressin-
induced elevation of plasma catecholamines in regard to the 
cannabinoid receptor subtypes. Central pretreatment with a 
selective antagonist of cannabinoid CB1 receptors AM 251 (180 
nmol/animal) significantly potentiated the vasopressin-induced 
responses. On the other hand, central pretreatment with a 
selective antagonist of cannabinoid CB2 receptors AM 630 even 
at a larger dose (793 nmol/animal) had a little effect on the 
vasopressin-induced responses. These results suggest that the 
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brain 2-arachidonoyl-sn-glycerol generated from diacylglycerol 
also has a negatively regulating effect on the vasopressin-
induced activation of adrenomedullary outflow through the 
brain cannabinoid CB1 receptor-mediated mechanisms in rats.
WIN 55212-2 has been shown to be a non-selective agonist 
of cannabinoid CB receptors (Felder et al., 1995). This 
reagent increases tail-flick reflexes, exerts antihyperalgesic 
effects and induces hypothermia in rats by central cannabinoid 
CB1 receptors (Martin et al., 1998; Fox et al., 2001; Rawls et 
al., 2002). In the present experiment, central pretreatment 
with WIN 55212-2 effectively reduced the vasopressin-induced 
elevation of plasma catecholamines, but peripheral 
pretreatment with this reagent had no effect. These results 
further support a possibility that the brain 2-arachidonoyl-
sn-glycerol generated from diacylglycerol also acts as an 
endocannabinoid, thereby negatively regulating the 
vasopressin-induced activation of adrenomedullary outflow in 
rats.
Cannabinoid has marked effects on peripheral autonomic 
neurons. Cannabinoid presynaptically inhibits the release of 
noradrenaline from many postganglionic sympathetic neurons 
(Malinowska et al., 1997; Niederhoffer and Szabo, 1999). On 
the other hand, only a few studies have been carried out to 
characterize the central effects of cannabinoid on the 
sympathetic nervous system. Intracisternally administered WIN 
55212-2 increased blood pressure and plasma noradrenaline 
concentration in rabbits and rats, respectively (Niederhoffer 
and Szabo, 2000; Pfitzer et al., 2004). Similarly, unilateral 
microinjection of WIN 55212-2 into the rostral ventrolateral 
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medulla oblongata, a crucial outflow pathway for centrally 
mediated sympathomodulatory effects, induced 
sympathoexcitation and hypertension in rats (Padley et al., 
2003). These lines of evidence suggest a possibility that 
centrally administered cannabinoid elicits sympathetic 
activation by acting on cardiovascular centers in the medulla 
oblongata. On the other hand, it is also reported that 
endocannabinoid released in the nucleus tractus solitarius 
prolongs baroreflex inhibition of renal sympathetic nerve 
activity (Seagard et al., 2004; Brozoski et al., 2005), 
suggesting the presence of endocannabinoid-induced 
sympathoinhibitory system in the brain. However, a central 
effect of cannabinoid on sympathetic nervous system in 
supramedullary cardiovascular centers such as hypothalamus has 
been scarcely studied. Further studies are necessary to 
clarify the mechanisms by which the brain 2-arachidonoyl-sn-
glycerol modulates the vasopressin-induced activation of 
adrenomedullary outflow in rats.
In summary, we demonstrated here a possibility that the 
brain 2-arachidonoyl-sn-glycerol has bidirectional roles in 
the centrally administered vasopressin-induced activation of 
adrenomedullary outflow in rats: (1) a source of free 
arachidonic acid for the brain cyclooxygenase, thereby 
activating adrenomedullary outflow; (2) a role of an 
endocannabinoid, thereby negatively regulating the 
vasopressin-induced response by brain cannabinoid CB1
receptors-mediated mechanisms.
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Legends to figures
Fig. 1. Effects of RHC-80267 (an inhibitor of diacylglycerol 
lipase) and MAFP (an inhibitor of monoacylglycerol lipase) on 
the vasopressin-induced elevation of plasma catecholamines. 
(A) RHC-80267 (1.3 and 2.6 ?mol/animal) or vehicle-1 (2.5 ?l
DMF/animal) was intracerebroventricularly (i.c.v.) 
administered 30 min before the administration of vasopressin 
(0.2 nmol/animal, i.c.v.) or vehicle-2 (10 ?l saline/animal, 
i.c.v.). (B) MAFP (0.7 and 1.4 ?mol/animal) or vehicle-1 (2.5 
?l DMF/animal) was i.c.v. administered 30 min before the 
administration of vasopressin (0.2 nmol/animal, i.c.v.) or 
vehicle-2 (10 ?l saline/animal, i.c.v.). ? Noradrenaline and ?
Adrenaline: increments of noradrenaline and adrenaline above 
the basal. Arrows indicate the intracerebroventricular 
administrations of RHC-80267/MAFP/vehicle-1 and 
vasopressin/vehicle-2. Each point represents the mean±S.E.M. 
*p<0.05, significantly different from vehicle-1- and 
vasopressin-treated group. Vehicle-1-treated groups in Fig. 1B 
were cited from Fig. 1A. The actual values for noradrenaline 
and adrenaline at 0 min were 309±37 and 516±115 pg/ml in the 
group pretreated with vehicle-1 (n=14); 346±31 and 518±38 
pg/ml in the group pretreated with RHC-80267 (1.3 ?mol/animal)
(n=6); 348±38 and 436±144 pg/ml in the group pretreated with 
RHC-80267 (2.6 ?mol/animal) (n=11); 395±13 and 503±101 pg/ml 
in the group pretreated with MAFP (0.7 ?mol/animal) (n=7); 
343±23 and 506±58 pg/ml in the group pretreated with MAFP (1.4 
?mol/animal) (n=11), respectively.
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Fig. 2. Effect of MAFP (an inhibitor of monoacylglycerol 
lipase) on the 2-arachidonoyl-sn-glycerol (2-AG)-induced 
elevation of plasma catecholamines. MAFP (1.4 ?mol/animal) or 
vehicle-1 (2.5 ?l DMF/animal) was i.c.v. administered 30 min 
before the administration of 2-AG (0.5 ?mol/animal, i.c.v.) or 
vehicle-2 (2.5 ?l DMF/animal). *p<0.05, significantly 
different from vehicle-1- and 2-AG-treated group. Other 
conditions were the same as those of Fig. 1. The actual values 
for noradrenaline and adrenaline at 0 min were 121±23 and 
92±18 pg/ml in the group pretreated with vehicle-1 (n=7); 
145±17 and 109±13 pg/ml in the group pretreated with MAFP (1.4
?mol/animal) (n=8), respectively.
Fig. 3. Effects of AM 251 (a selective antagonist of 
cannabinoid CB1 receptors) and AM 630 (a selective antagonist 
of cannabinoid CB2 receptors) on the vasopressin-induced 
elevation of plasma catecholamines. (A) AM 251 (90 and 180 
nmol/animal) or vehicle-1 (2.5 ?l DMF/animal) was i.c.v. 
administered 30 min before the administration of vasopressin 
(0.2 nmol/animal, i.c.v.) or vehicle-2 (10 ?l saline/animal, 
i.c.v.). (B) AM 630 (198 and 793 nmol/animal) or vehicle-1 
(2.5 ?l DMF/animal) was i.c.v. administered 30 min before the 
administration of vasopressin (0.2 nmol/animal, i.c.v.) or 
vehicle-2 (10 ?l saline/animal, i.c.v.). Vehicle-1-treated 
groups were cited from Fig. 1A. *p<0.05, significantly 
different from vehicle-1- and vasopressin-treated group. Other 
conditions were the same as those of Figs. 1 and 2. The actual 
values for noradrenaline and adrenaline at 0 min were 402±65 
and 520±126 pg/ml in the group pretreated with AM 251 (90 
32
nmol/animal) (n=5); 358±58 and 584±156 pg/ml in the group 
pretreated with AM 251 (180 nmol/animal) (n=12); 387±23 and 
587±89 pg/ml in the group pretreated with AM 630 (198 
nmol/animal) (n=6); 343±16 and 481±80 pg/ml in the group 
pretreated with AM 630 (793 nmol/animal) (n=9), respectively.
Fig. 4. Effect of WIN 55212-2 (an agonist of cannabinoid CB 
receptors) on the vasopressin-induced elevation of plasma 
catecholamines. WIN 55212-2 (188 and 470 nmol/animal) or 
vehicle-1 (2.5 ?l DMF/animal) was i.c.v. administered 60 min 
before the administration of vasopressin (0.2 nmol/animal, 
i.c.v.) or vehicle-2 (10 ?l saline/animal, i.c.v.). *p<0.05,
significantly different from vehicle-1- and vasopressin-
treated group. Other conditions were the same as those of 
Figs. 1-3. The actual values for noradrenaline and adrenaline 
at 0 min were 286±36 and 385±129 pg/ml in the group pretreated 
with vehicle-1 (n=13); 214±24 and 331±41 pg/ml in the group 
pretreated with WIN 55212-2 (188 nmol/animal) (n=6); 247±35 
and 369±119 pg/ml in the group pretreated with WIN 55212-2 
(470 nmol/animal) (n=10), respectively.
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